Unicycive Therapeutics Advances Kidney Disease Treatment with New Patent
Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a clinical-stage biotechnology company based in California, proudly announces the issuance of U.S. Patent 12,377,082 by the U.S. Patent and Trademark Office for its innovative drug UNI-494, aimed at treating Chronic Kidney Disease (CKD). This patent strengthens its intellectual property portfolio, following a prior method of use patent concerning the treatment of Acute Kidney Injury (AKI) with UNI-494.
Significance of the New Patent
“As we strive for FDA approval of our primary product, oxylanthanum carbonate, the announcement of the patent for UNI-494 is a promising development for our second investigational drug,” expressed Shalabh Gupta, MD, CEO of Unicycive Therapeutics. This intellectual property coverage signifies additional opportunities for partnerships that could accelerate further research and development initiatives.
Progress and Innovations
Unicycive has successfully completed a Phase I clinical study involving healthy volunteers for UNI-494. The drug has also achieved Orphan Drug Designation from the FDA, specifically for preventing Delayed Graft Function (DGF) in kidney transplant patients, showcasing its potential as a groundbreaking treatment option.
Understanding UNI-494 and Its Mechanism
UNI-494 is a novel nicotinamide ester derivative functioning as a selective ATP-sensitive mitochondrial potassium channel activator. This innovative mechanism may be pivotal in restoring mitochondrial function—crucial for patients experiencing acute kidney injury and chronic kidney disease. Patent protections extend across the U.S., Europe, and various global applications, accentuating the drug's significance in the medical realm.
The Challenge of Acute Kidney Injury
Acute kidney injury (AKI) remains a significant concern, defined by a sudden decline in kidney performance, which has implications for survival and long-term health. The causes of AKI range from sepsis and ischemia to drug-induced effects, creating urgent healthcare needs. Notably, DGF represents a particular type of AKI that emerges shortly after a kidney transplant, affecting half of transplant patients. With such a high incidence, addressing these complications is critical.
About Unicycive Therapeutics
Unicycive Therapeutics focuses on developing revolutionary treatments targeting kidney diseases. The company’s lead investigational option, oxylanthanum carbonate, addresses hyperphosphatemia in CKD patients on dialysis. Meanwhile, UNI-494 seeks to combat conditions related to acute kidney injuries and has also shown promise in its Phase 1 safety studies.
For more detailed insights about our research and breakthrough products, feel free to visit our website for updates, as we also maintain an active presence on various professional networks.
Frequently Asked Questions
What is UNI-494 and how does it work?
UNI-494 is a novel drug designed to activate mitochondrial potassium channels, potentially restoring mitochondrial function and aiding in the treatment of various kidney diseases.
What recent patent has Unicycive Therapeutics received?
The company has announced the U.S. Patent 12,377,082 for UNI-494, specifically aimed at treating Chronic Kidney Disease.
What is the purpose of Orphan Drug Designation?
Orphan Drug Designation is granted to drugs that treat rare conditions, allowing for incentives such as market exclusivity, tax credits, and assistance in the development process.
What does the Phase I clinical study entail?
The Phase I clinical study is a safety trial involving healthy volunteers to assess the drug's safety profile before further efficacy studies.
How are acute kidney injuries relevant to UNI-494?
UNI-494 aims to treat conditions resulting from acute kidney injuries, which are critical health issues for many patients, especially following kidney transplants.
